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comprehensive review of benefits and risks based on 8 randomized 
studies in 2023 patients with respiratory cancers
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Background: For more than a decade, ESAs (epoetin alpha and beta, 
and darbepoetin) have been routinely used in cancer treatment. A 
series of reports over the past 5 years has raised concern about ESAs; 
as such the US FDA has now issued a boxed safety warning due to 
thrombotic risk and adverse survival ﬁndings. Beneﬁts of ESAs based 
on a Cochrane meta-analysis are raising of hemoglobin (Hb, average 
about 1g) and transfusion reduction (average 1 unit), without consistent 
quality of life advantages (Bohlius JNCI 2006, ASCO/ASH guidelines, 
Blood 2002). Negative ﬁndings concerning local control and survival 
were ﬁrst published in head and neck cancer (Henke, Lancet 2003) and 
7 more studies in this malignancy and lung cancer followed involving 
patients treated with chemotherapy, RT, or both. Additional concern has 
come from reports of markedly increased thrombosis when ESAs are 
added to antiangiogenic agents. The above 2006 metaanalysis reported 
detrimental hazard ratios of 1.67 for thrombosis and 1.08 for survival 
(but 1.16 in disease-speciﬁc studies). We conducted this analysis to 
investigate overall results in respiratory malignancies and to view the 
appropriateness of the reporting and conduct of the trials.
Methods: A comprehensive review of all randomized head and neck, 
small cell and non-small cell lung cancer ESA trials was conducted. 
Cancer-related endpoints were required to have been assessed in the 
trials but were not required to be primary endpoints. Literature search 
included medline, abstracts and regulatory documents.
Results: 8 studies met criteria. 2023 patients are included (1012 
control, 417 epoetin-alpha, 180 epoetin-beta, 414 darbepoetin). As 
summarized in the table, the majority of the randomized respiratory 
malignancy-oriented trials were suspended or terminated early (75%), 
and reported excess thrombosis (75%), or survival not favoring ESA 
use (87%). 
 
 
Number of  
Studies (%)
Number of Patients
Primary endpoint 
 Cancer related 6 (75) 1639
 Hb/transfusions 2 (25) 384
Study status
 Completed 2 (25) 665
 Suspended 6 (75) 1358
Thrombotic events 
ESA vs control Increased 6 (75) 1639
 No diﬀerence 2 (25) 384
Survival favors 
 Control 7 (87) 1709
 ESA 1 (13) 314
Reporting status 
 Published 4 (50) 959
 Abstract 2 (25) 247
 Regulatory docu-ments only 2 (25) 817
 
Conclusion: ESAs in respiratory cancers are associated with substan-
tial thrombotic risk and negative tumor or survival endpoints in ran-
domized studies. Additionally, while these studies targeted hemoglobin 
levels above 12g/dl, there is no conclusive evidence from these studies 
that lower hemoglobin levels are safe, or that a safe level has been es-
tablished. Several mechanisms concerning these negative ﬁndings can 
be hypothesized. It is clear that caution should be exercised in the use 
of ESAs in respiratory cancers and that new guidelines are imperative.
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Screening for the supportive care needs of patients with lung 
cancer identifies high levels of unmet need 
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Introduction: Lung cancer is a highly symptomatic disease resulting in 
frequent debility and psychosocial distress that may go undetected. Op-
timal care involves not only treatment of the disease, but also symptom 
management and identiﬁcation of additional supportive care needs. 
Methods: The unit nurse coordinator assesses all new patients referred 
to our lung service soon after their ﬁrst initial consultation with a doc-
tor. A detailed patient - completed screening tool has been designed to 
identify supportive care needs and prompt appropriate referrals within 
the lung team. We audited the results of 197 out-patients who com-
pleted the screening tool over the last 2 years.
Results: Median age was 65 years (range 25-85) with 36% females. 
43% had metastatic disease. Patients reported high rates of concern 
about signiﬁcant symptoms including fatigue (68%), dyspnoea (56%), 
pain (38%), weight loss (33%), nausea and vomiting (29%), and bowel 
disturbance (28%). 35% rated their own ECOG performance status 
(PS) as 2 or higher. Patient and physician-rated ECOG was moderately-
well correlated (R = 0.494, p < 0.001), with patients rating their ECOG 
as higher than the physician when there was a discrepancy. Prominent 
needs for practical help included assistance with transport (33%), shop-
ping (25%), cooking (16%), and ﬁnances (17%). Pts with signiﬁcant 
weight-loss were more likely to report other problematic physical 
symptoms, have a poorer ECOG PS and need for practical help with 
cooking and shopping. However only 78% lived with another adult, 
19% cared for dependents and 12% reported that no one was available 
to help. High needs for further information about treatments, side-ef-
fects, diet, complementary therapies and prognosis were identiﬁed 
in more than a third of patients. Many patients reported symptoms to 
suggest signiﬁcant depression (41%) and anxiety (29%). Fifty percent 
felt that their usual social interactions with family and friends were 
moderately to extremely limited, and 25% reported that they had no 
one to talk to about their feelings and concerns. These ﬁndings resulted 
in the majority of patients requiring additional referrals to medical and 
allied health staff (table).
Conclusions: Use of a screening tool in patients with lung cancer at 
diagnosis is feasible and identiﬁes high needs for additional support-
ive care to address symptoms, practical issues, information needs and 
psychosocial distress. Further research into the utility of interventions 
designed to meet these needs is required along with exploration of 
